Galapagos Touts Positive Post-Hoc Data, but Likely Won’t Gun for US Approval

Despite a disappointment on U.S. shores, Galapagos is forging ahead with its JAK1 inhibitor for ulcerative colitis (UC). The Belgium-based company announced new post-hoc analyses from its Phase III SELECTION program touting rapid symptom improvement and sustained steroid-free remission.